Price$13.78+0.01 (+0.07%)
01:30 PM04:30 PM
News · 26 weeks57+50%
2026-04-192026-10-11
Mix1590d
- Other8(53%)
- SEC Filings3(20%)
- Insider2(13%)
- Leadership1(7%)
- Dividends1(7%)
Latest news
25 items- PROrganon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual MeetingNo new safety signals identified during additional three years of extended use Organon holds exclusive global licensing rights to MIUDELLA Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Women’s Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA®, a hormone-free, copper intrauterine device (IUD), through 6 years of use at the 2026 Society of Family Planning (SFP) Annual Meeting, taking place October 17 to 19, 2026, in San Francisco, California. In June 2026, Organon exclusively licensed global rights to MIUDELLA from Sebela Women’s Heal
- PROrganon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology ConferenceNew data will represent one of the first large-scale real-world effectiveness analyses of VTAMA cream in patients with atopic dermatitis (AD) Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new real-world analysis of patients with atopic dermatitis (AD) treated with VTAMA® (tapinarof) cream, 1% will be on display at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada. The analysis, entitled Real World Effectiveness of Tapinarof 1% Cream for Atopic Dermatitis, evaluates VTAMA’s effectiveness in real-world settings, including improvements in physician-reported outco
- PROrganon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and OlderKIRKLAND, QC, Sept. 28, 2026 /CNW/ -- Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult and pediatric patients 2 years of age and older. "Winter is coming, and with it, the dry, cold, and windy climate that frequently results in flares for patients with atopic dermatitis, an inflammatory skin condition that can have a significant impact on sleep, mental health, and quality of life. The approval and now availability of tapinarof cream are welcome additions to the range of treatment
- PROrganon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine DeviceSebela’s sNDA Seeks to Extend Approved Duration of Use from 3 to 6 Years Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the US Food and Drug Administration (FDA) has accepted for review Sebela Women’s Health’s supplemental New Drug Application (sNDA) for MIUDELLA® (copper intrauterine system) for an extended duration of use for up to 6 years with Prescription Drug User Fee Act (PDUFA) action expected in the second quarter of calendar year 2027. In June of 2026, Organon completed its agreement to exclusively license global rights to Sebela’s MIUDELLA. MIUDELLA is a hormone-free, copper
- PRNational Can-RISE Study to Help Close Critical Gaps in Menopause ResearchTORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada (WHCC) and the Partnership for Women’s Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Information, Support, and Equity During the Menopause Transition in Canada (Can-RISE) Study. As the first national investigator-led study focused on Canadian women’s experiences of menopause and the menopausal transition, Can-RISE is led by PWHR with funding support from WHCC. The Can-RISE Study builds on the recently announced partnership between Women’s Health Collective Canada and GreenShield, Canada's only national non-profit healt
- SECSEC Form SCHEDULE 13G filed by Organon & Co.SCHEDULE 13G - Organon & Co. (0001821825) (Subject)
- INSIDERHead of R&D & CMO Arjona Ferreira Juan Camilo converted options into 11,519 shares and covered exercise/tax liability with 4,134 shares, increasing direct ownership by 25% to 37,432 units (SEC Form 4)4 - Organon & Co. (0001821825) (Issuer)
- PROrganon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial AvailabilityHealthcare Providers, Healthcare Settings, and Participating Pharmacies Can Now Begin Required Training and Certification in Preparation for MIUDELLA’s Launch Later This Year Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the MIUDELLA® (copper intrauterine system) Risk Evaluation and Mitigation Strategy (REMS) Program is now open for enrollment at www.miudellarems.com. The website enables healthcare providers, healthcare settings, and eligible specialty pharmacies to complete the certification and enrollment activities required to support the dispensing and insertion of MIUDELLA. MIUD
- INSIDERHead of Mfg & Supply Drinane Juliana Papa sold $200,307 worth of shares (14,761 units at $13.57), decreasing direct ownership by 44% to 18,475 units (SEC Form 4)4 - Organon & Co. (0001821825) (Issuer)
- PROrganon Announces Quarterly DividendOrganon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE:OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on
- SECOrganon & Co. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Organon & Co. (0001821825) (Filer)
- SECSEC Form 10-Q filed by Organon & Co.10-Q - Organon & Co. (0001821825) (Filer)
- PRNew Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD®) and ≥75% improvement in Eczema Area and Severity Index (EASI75) over time has been broken out into pediatric and adult age subsets1 VTAMA demonstrated consistent improvements in skin clearance and disease severity, as measured by the vIGA-AD and EASI1 Across pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of the 8-week treatment period1 Organon
- SECSEC Form 8-K filed by Organon & Co.8-K - Organon & Co. (0001821825) (Filer)
- PRORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR25-year industry leader to drive continued growth and expand access to medicines in CanadaKIRKLAND, QC, July 22, 2026 /CNW/ -- Organon Canada, a global healthcare company dedicated to improving the health of women, is pleased to announce the appointment of Dominic Bégin as President and Managing Director. In this role, Mr. Bégin will lead the organization's strategic and commercial agenda, strengthen its leadership in key therapeutic areas, and expand access to cost-effective solutions, including biosimilars, for governments and payers across Canada. "I am honoured to take on this role and continue building on the strong founda
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form 8-K filed by Organon & Co.8-K - Organon & Co. (0001821825) (Filer)
- PROrganon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q FilingOrganon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission ("SEC"). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will be disclosed in a Form 8-K filing to be filed on the same day as the Form 10-Q. During the pendency of the previously announced acquisition by Sun Pharmaceutical Industries Limited on April 26, 2026, Organon has suspended its quarterly e
- PROrganon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual MeetingNew analysis of pooled Phase 3 data will evaluate efficacy and safety of VTAMA cream across age groups in pediatric and adult patients with atopic dermatitis (AD) Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in AD will be presented at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting, taking place July 22 – 25, 2026, in Minneapolis, Minnesota. The presentation includes a pooled post hoc analysis of data from the pivotal Phase 3 ADORING 1 and ADORING 2 clinical trials evaluating the efficacy and safety of VTAMA
- PROrganon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVAThe launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas Organon Canada and Shanghai Henlius Biotech, Inc. (2696.HK) today announced that BILDYOS® (denosumab injection) 60 mg/1 mL and TUZEMTY® (denosumab injection) 120 mg/1.7 mL, biosimilars to PROLIA and XGEVA, respectively, are now available in Canada for all indications of reference products. Used across several indications, denosumab products treat osteoporosis and bone events associated with cancer by helping to strengthen bones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623760250/en/ "The approvals represent a
- PROrganon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine DeviceThis transaction strengthens Organon’s contraception portfolio and expands long-acting reversible options for women Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA®, a hormone-free, copper intrauterine device (IUD). Please see our prior announcement for a summary of the transaction terms. Approved by the US Food and Drug Administration (FDA) on February 24, 2025, MIUDELLA is the first hormone-free copper IUD to be introduced in the US in over 40 years. Indicated for
- PROrganon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in CanadaThe amended agreement deepens Organon and Samsung Bioepis's collaboration to six biosimilars in Canada across multiple therapeutic areas, including immunology, oncology and dermatology. To be launched in Canada in 2026 Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to PYZCHIVA®, Samsung Bioepis's biosimilar referencing STELARA® (ustekinumab). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618749080/en/ PYZCHIVA® is indicated for the tre
- SECSEC Form DEFM14A filed by Organon & Co.DEFM14A - Organon & Co. (0001821825) (Filer)
- INSIDERSEC Form 4 filed by Director Sharp Shalini4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Sequeira Ramona4 - Organon & Co. (0001821825) (Issuer)
OGN FAQ
8 questionsWhat does Organon & Co. do?
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a...Where does OGN stock trade?
Organon & Co. (OGN) is listed on NYSE.What sector and industry is OGN in?
Organon & Co. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Organon & Co. go public?
Organon & Co. (OGN) completed its IPO in 2021.Does OGN pay a dividend?
OGN's most recent ex-dividend date was 2026-08-14 with a cash dividend of $0.02 per share. No future ex-date is on file yet.What are analysts saying about OGN?
Organon & Co. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $1400.00 price target on 2026-04-28.What companies are similar to OGN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare OGN side-by-side with any of them on Quantisnow.How can I track OGN on Quantisnow?
Quantisnow aggregates Organon & Co.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OGN to receive live email and push alerts on every new disclosure.